Vetter Dedicates New Facility in Suburban Chicago
Skokie, Illinois
With the dedication today of its new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, Vetter may enable life-sciences firms to streamline their early development process and cut time to market. Vetter, a contract manufacturer, produces aseptically pre-filled injection systems including syringes, vials and injection pens and is mainly engaged in the field of fill and finishing of compounds indicated for conditions such as cancer, Parkinson’s disease, and inflammatory and autoimmune disorders. Vetter also manufactures its customers´ vaccines, including that for the H1N1 virus.
Operational by the end of 2010, the Skokie facility will focus exclusively on pre-clinical through Phase IIb projects and will fill very small quantities of product, required for early studies. For Phase III the projects will be transferred to the company’s German facilities for large-scale production. The new facility to be located in Chicago, IL.
“Since nearly half of our customer base is located in North America, creating a U.S. facility was the logical next step,” said Peter Soelkner, Vetter`s managing director.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
